Trial Profile
Protocol H3E-MC-JMIG Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms JMIG; PROCLAIM
- Sponsors Eli Lilly and Company
- 04 May 2018 Results of subgroup analysis assessing impact of PET on overall survival and progression-free survival published in the Journal of Thoracic Oncology.
- 11 Oct 2016 Results from post-hoc subgroup analyses based on positron emission tomography (PET) scan use in non-small cell lung cancer patients presented at the 41st European Society for Medical Oncology Congress.
- 07 Jun 2016 Results (n=555) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology